Cardio Diagnostics Inc.  

• Home
• Press Releases
• Products
• Additional Info

Epi+Gen CHD™

A clinical blood test available via prescription only, to assess the three-year-risk for a coronary heart disease event, including a heart attack or sudden death, using epigenetics, genetics, and artificial intelligence.... More Info Less Info





Epi+Gen CHD™ is a clinical test that assesses the 3-year risk for a coronary heart disease (CHD) event. CHD is the most common type of heart disease and the primary cause of heart attacks. This highly sensitive and accessible blood test that profiles a panel of genetic and epigenetic biomarkers is radiation-free, does not require fasting, and can be conducted remotely or in provider settings.

In a peer-reviewed study done in collaboration with Intermountain Healthcare and published in Epigenomics in June 2021¹, Epi+Gen CHD™ demonstrated a 76% and 78% sensitivity for men and women, respectively, for 3-year CHD event risk prediction compared to the average sensitivity of the lipid-based Framingham Risk Score and ASCVD Pooled Cohort Equation tests that was 44% sensitive for men and 32% sensitive for women.


PrecisionCHD™
A clinical blood test available via prescription only, to detect and manage the presence of coronary heart disease using epigenetics, genetics, and artificial intelligence.... More Info Less Info



PrecisionCHD™ is a powerful test that combines epigenetics, genetics and artificial intelligence to assess the presence of coronary heart disease (CHD), the most common type of heart disease and the major cause of heart attacks. PrecisionCHD™ addresses the shortcomings of current detection tests because it:
• Demonstrates strong clinical value with 80% sensitivity for men and 76% sensitivity for women, compared to the sensitivity of exercise ECG of 45-68% ⁽¹⁾ ⁽²⁾ ⁽³⁾
• Is a simple, non-invasive blood test performed in a high complexity CLIA lab
• Sample can be collected at-home or in provider settings without the need to wait weeks or months to get tested
• Does not require fasting or exposure to radiation
• Is coupled to Cardio Diagnostics’ Actionable Clinical Intelligence™ platform to assist clinicians in personalizing clinical decisions

Actionable Clinical Intelligence™ (ACI™)
Actionable Clinical Intelligence™ is a platform combines test results with epigenetic, genetic markers, and clinical info, providing clinical insights into coronary heart disease factors.... More Info Less Info



Actionable Clinical Intelligence™ (ACI™) is a platform available to providers who prescribe Epi+Gen CHD™ and PrecisionCHD™, linking the patient‘s unique epigenetic and genetic biomarkers to modifiable drivers of heart disease.
We believe shared decision-making in healthcare is essential for providers and their patients, and ACI makes this a reality. Insights from ACI™:
• Integrated test results with a patient’s unique epigenetic and genetic biomarkers together with clinical information to provide deeper and actionable insights to providers about factors driving the patient’s coronary hear about factors driving the patient’s coronary heart disease disease.
• Tailored to each patient to help elucidate areas of concern and aid a clinician’s independent assessment, with the goal of improving patient outcomes.
• The relative contribution of each of the patient’s biomarkers to CHD, evidence on the role of these biomarkers in coronary heart disease pathogenesis, and changes in the measured biomarkers over time in response to lifestyle and therapeutic interventions.

We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!

First time Exhibitor?